4.88
Diamedica Therapeutics Inc Aktie (DMAC) Neueste Nachrichten
The Beat: Entrust names new CEO, DiaMedica raises millions - The Business Journals
DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement - BioSpace
DiaMedica Therapeutics Secures $30.1 Million in Private Placement - TipRanks
DiaMedica Therapeutics closes $30.1 million private placement - Investing.com India
Is DiaMedica Therapeutics Inc. a good long term investmentDynamic profit expansion - jammulinksnews.com
DiaMedica Therapeutics Inc. Stock Analysis and ForecastOutperformance with explosive growth - jammulinksnews.com
What drives DiaMedica Therapeutics Inc. stock priceExtraordinary market timing - jammulinksnews.com
What analysts say about DiaMedica Therapeutics Inc. stockFree Stock Market Knowledge Sharing - jammulinksnews.com
Diamedica Therapeutics shares rise 11.01% intraday after $30.1M private placement and positive trial results for DM199 in preeclampsia. - AInvest
DiaMedica Announces $30.1M Private Placement for DM199 - TipRanks
DiaMedica secures $30.1 million in private placement for clinical trials By Investing.com - Investing.com South Africa
DiaMedica secures $30.1 million in private placement for clinical trials - Investing.com
DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline - Business Wire
DiaMedica Therapeutics (NASDAQ:DMAC) Price Target Raised to $12.00 - Defense World
DiaMedica shares drop 35% following InvestingPro’s overvalued warning By Investing.com - Investing.com India
DiaMedica gains on positive mid-stage trial data for lead drug in preeclampsia - MSN
What makes DiaMedica Therapeutics Inc. stock price move sharplyReliable High Profit Alerts - beatles.ru
DiaMedica stock price target raised to $12 from $10 at H.C. Wainwright - Investing.com
DiaMedica Therapeutics to be included in the Russell 2000 and 3000 indexes - MSN
DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer - BioSpace
DiaMedica Therapeutics reports interim results from DM199 study - TipRanks
DiaMedica Announces Positive Interim Results for DM199 Study - TipRanks
DiaMedica reports positive interim results for preeclampsia treatment - Investing.com
Why DiaMedica Therapeutics Inc. stock attracts strong analyst attentionVerified Return Tips - Newser
How DiaMedica Therapeutics Inc. stock performs during market volatilityValue Pick Scanner - Newser
3 Promising Penny Stocks With Market Caps Under $200M - simplywall.st
Trend Tracker for (DMAC) - news.stocktradersdaily.com
DiaMedica Therapeutics Inc.(NasdaqCM: DMAC) added to Russell 2000 Dynamic Index - MarketScreener
DiaMedica Therapeutics Inc.(NasdaqCM: DMAC) added to Russell 3000 Growth Index - MarketScreener
DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes - Business Wire
DiaMedica Therapeutics Insiders Up US$4.1m On US$9.00m Investment - simplywall.st
Millennium Management LLC Increases Holdings in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
42,212 Shares in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Purchased by Jane Street Group LLC - Defense World
Can DiaMedica Deliver A Breakthrough In Preeclampsia Treatment? - RTTNews
Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Increases By 38.3% - Defense World
Lake Street Keeps Their Buy Rating on Diamedica Therapeutics (DMAC) - The Globe and Mail
Northern Trust Corp Has $978,000 Holdings in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
DMAC: HC Wainwright & Co. Reiterates Buy Rating with $10 Price T - GuruFocus
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):